Pneuma Respiratory and Leads Biolabs Partnership

Pneuma Respiratory, Inc., developer of a proprietary breath-activated digital inhaler (BDI), and Leads Biolabs Inc. announce an agreement granting Pneuma an exclusive license to develop Leads Biolabs’ panel of immuno-oncology monoclonal antibodies and fusion protein molecules for the pulmonary delivery of Leads’ antibodies and molecules.  Using Pneuma’s digital inhaler platform, the agreement provides access to the untapped potential of pulmonary delivery of Leads’ immuno-oncology therapies in the treatment of oncologic or immune-mediated lung diseases.

In a recent publication, Pneuma announced the completion of a study demonstrating the feasibility of antibody delivery to the lungs via its digital inhaler platform.  This study, conducted in an animal model, indicates that the Pneuma digital inhaler platform may provide a method for the pulmonary delivery of monoclonal antibody therapies, enabling the targeted treatment of oncologic or immune-mediated lung diseases.

“This collaboration is an exciting development for the field of immuno-oncology,” said Ronald Bukowski, MD, physician emeritus, Cleveland Clinic Foundation.  “Approaches utilizing the regional administration of novel checkpoint inhibitors may provide new treatment opportunities for patients with a variety of malignancies.”

“We are pleased to enter into a license agreement for Leads Biolabs monoclonal antibody portfolio,” said Pneuma Chief Executive Officer and co-founder Eric Hunter. “We look forward to working with their team to conduct studies that may lead to positive change in the future treatment of non-small cell lung cancer.”

Dr. Xiaoqiang Kang, Chairman and CEO of Leads Biolabs, said: “We are very excited to have this license agreement with Pneuma Respiratory. The commitment by a leader in digital pulmonary delivery of drugs is an endorsement of the value of our portfolio. We believe that Pneuma’s digital inhaler technology combined with our antibody drugs will create very exciting new opportunities for both companies. We look forward to working with Pneuma to move our candidates into the clinic as quickly as possible.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here